H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The firm sees potential FDA approval by November 30 for the combination of epcoritamab plus rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s Tisotumab Vedotin Study: A Promising Update for Solid Tumor Treatment
- Genmab’s Cervical Cancer Study: A Potential Game-Changer?
- Genmab Updates Articles to Boost Financial Flexibility
- Genmab’s Earnings Call Highlights Strong Growth and Pipeline Success
- Genmab Announces Capital Increase Following Employee Warrant Exercise